Carbapenem-Resistant Enterobacteriaceae

Alina Iovleva, Yohei Doi

研究成果: ジャーナルへの寄稿総説査読

142 被引用数 (Scopus)

抄録

Carbapenem-resistant Enterobacteriaceae (CRE) have emerged as a major threat. Commonly used antibiotics are generally inactive against CRE. Therefore, timely detection of CRE is of paramount importance. Among CRE, those producing carbapenem-hydrolyzing β-lactamase enzymes (carbapenemase-producing Enterobacteriaceae) are particularly of concern because they tend to spread, and treatment is difficult. The carbapenemase groups most commonly encountered include KPC, NDM, and OXA-48. Treatment options are limited and include combinations of polymyxins, tigecycline, aminoglycosides, or carbapenems; newer agents with activity against CRE and better safety profiles are becoming available and will likely emerge as the preferred therapy.

本文言語英語
ページ(範囲)303-315
ページ数13
ジャーナルClinics in Laboratory Medicine
37
2
DOI
出版ステータス出版済み - 06-2017
外部発表はい

All Science Journal Classification (ASJC) codes

  • 臨床生化学
  • 生化学、医学

フィンガープリント

「Carbapenem-Resistant Enterobacteriaceae」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル